Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy

Augmentation with cyclophosphamide and correlation with response

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, J. C. Yang

Research output: Contribution to journalArticle

Abstract

Background. The adoptive transfer of interleukin-2 [IL-2]-cultured tumor infiltrating lymphocytes (TIL) can cause tumor regression in patients with metastatic melanoma. Methods. Thirty-eight patients with metastatic melanoma receiving high dose IL-2 and TIL were studied for the ability of autologous 111In-labeled TIL to localize to metastatic tumor deposits by gamma camera imaging and biopsy. Single bolus cyclophosphamide was administered 24-36 hours before TIL infusion in 27 treatment courses. Results. Tumor localization by 111In-labeled TIL was seen by gamma camera imaging in 26 (68.4%) treatment courses. In a univariate analysis of factors influencing TIL traffic, cyclophosphamide administration was significantly associated with the ability to localize tumor by radionuclide imaging (P2 = 0.026). Twenty-one of 26 (80.8%) treatment courses given with cyclophosphamide demonstrated tumor localization, compared with only 5 of 12 (41.7%) treatment courses without cyclophosphamide. In addition, patients whose 111In- labeled TIL imaged their tumor received significantly more TIL than did those that did not (P2 = 0.0052). Biopsies revealed a greater accumulation of 111In in cutaneous tumors than in normal skin biopsy specimens (0.0021 and 0.0004% injectate/gram of tissue, respectively; P2 = 111In-TIL. Cyclophosphamide administration before TIL and IL-2 therapy and the administration of large numbers of TIL appear to improve the frequency of TIL localization to tumor.

Original languageEnglish (US)
Pages (from-to)1731-1737
Number of pages7
JournalCancer
Volume73
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Adoptive Immunotherapy
Cyclophosphamide
Neoplasms
Radionuclide Imaging
Interleukin-2
Biopsy
Melanoma
Therapeutics
Skin
Adoptive Transfer
Statistical Factor Analysis

Keywords

  • cyclophosphamide
  • immunotherapy
  • melanoma
  • radio imaging
  • tumor infiltrating lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pockaj, B. A., Sherry, R. M., Wei, J. P., Yannelli, J. R., Carter, C. S., Leitman, S. F., ... Yang, J. C. (1994). Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: Augmentation with cyclophosphamide and correlation with response. Cancer, 73(6), 1731-1737.

Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy : Augmentation with cyclophosphamide and correlation with response. / Pockaj, B. A.; Sherry, R. M.; Wei, J. P.; Yannelli, J. R.; Carter, C. S.; Leitman, S. F.; Carasquillo, J. A.; Steinberg, S. M.; Rosenberg, S. A.; Yang, J. C.

In: Cancer, Vol. 73, No. 6, 1994, p. 1731-1737.

Research output: Contribution to journalArticle

Pockaj, BA, Sherry, RM, Wei, JP, Yannelli, JR, Carter, CS, Leitman, SF, Carasquillo, JA, Steinberg, SM, Rosenberg, SA & Yang, JC 1994, 'Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: Augmentation with cyclophosphamide and correlation with response', Cancer, vol. 73, no. 6, pp. 1731-1737.
Pockaj, B. A. ; Sherry, R. M. ; Wei, J. P. ; Yannelli, J. R. ; Carter, C. S. ; Leitman, S. F. ; Carasquillo, J. A. ; Steinberg, S. M. ; Rosenberg, S. A. ; Yang, J. C. / Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy : Augmentation with cyclophosphamide and correlation with response. In: Cancer. 1994 ; Vol. 73, No. 6. pp. 1731-1737.
@article{e687a4128dac46a69b3a11521675dc61,
title = "Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: Augmentation with cyclophosphamide and correlation with response",
abstract = "Background. The adoptive transfer of interleukin-2 [IL-2]-cultured tumor infiltrating lymphocytes (TIL) can cause tumor regression in patients with metastatic melanoma. Methods. Thirty-eight patients with metastatic melanoma receiving high dose IL-2 and TIL were studied for the ability of autologous 111In-labeled TIL to localize to metastatic tumor deposits by gamma camera imaging and biopsy. Single bolus cyclophosphamide was administered 24-36 hours before TIL infusion in 27 treatment courses. Results. Tumor localization by 111In-labeled TIL was seen by gamma camera imaging in 26 (68.4{\%}) treatment courses. In a univariate analysis of factors influencing TIL traffic, cyclophosphamide administration was significantly associated with the ability to localize tumor by radionuclide imaging (P2 = 0.026). Twenty-one of 26 (80.8{\%}) treatment courses given with cyclophosphamide demonstrated tumor localization, compared with only 5 of 12 (41.7{\%}) treatment courses without cyclophosphamide. In addition, patients whose 111In- labeled TIL imaged their tumor received significantly more TIL than did those that did not (P2 = 0.0052). Biopsies revealed a greater accumulation of 111In in cutaneous tumors than in normal skin biopsy specimens (0.0021 and 0.0004{\%} injectate/gram of tissue, respectively; P2 = 111In-TIL. Cyclophosphamide administration before TIL and IL-2 therapy and the administration of large numbers of TIL appear to improve the frequency of TIL localization to tumor.",
keywords = "cyclophosphamide, immunotherapy, melanoma, radio imaging, tumor infiltrating lymphocytes",
author = "Pockaj, {B. A.} and Sherry, {R. M.} and Wei, {J. P.} and Yannelli, {J. R.} and Carter, {C. S.} and Leitman, {S. F.} and Carasquillo, {J. A.} and Steinberg, {S. M.} and Rosenberg, {S. A.} and Yang, {J. C.}",
year = "1994",
language = "English (US)",
volume = "73",
pages = "1731--1737",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy

T2 - Augmentation with cyclophosphamide and correlation with response

AU - Pockaj, B. A.

AU - Sherry, R. M.

AU - Wei, J. P.

AU - Yannelli, J. R.

AU - Carter, C. S.

AU - Leitman, S. F.

AU - Carasquillo, J. A.

AU - Steinberg, S. M.

AU - Rosenberg, S. A.

AU - Yang, J. C.

PY - 1994

Y1 - 1994

N2 - Background. The adoptive transfer of interleukin-2 [IL-2]-cultured tumor infiltrating lymphocytes (TIL) can cause tumor regression in patients with metastatic melanoma. Methods. Thirty-eight patients with metastatic melanoma receiving high dose IL-2 and TIL were studied for the ability of autologous 111In-labeled TIL to localize to metastatic tumor deposits by gamma camera imaging and biopsy. Single bolus cyclophosphamide was administered 24-36 hours before TIL infusion in 27 treatment courses. Results. Tumor localization by 111In-labeled TIL was seen by gamma camera imaging in 26 (68.4%) treatment courses. In a univariate analysis of factors influencing TIL traffic, cyclophosphamide administration was significantly associated with the ability to localize tumor by radionuclide imaging (P2 = 0.026). Twenty-one of 26 (80.8%) treatment courses given with cyclophosphamide demonstrated tumor localization, compared with only 5 of 12 (41.7%) treatment courses without cyclophosphamide. In addition, patients whose 111In- labeled TIL imaged their tumor received significantly more TIL than did those that did not (P2 = 0.0052). Biopsies revealed a greater accumulation of 111In in cutaneous tumors than in normal skin biopsy specimens (0.0021 and 0.0004% injectate/gram of tissue, respectively; P2 = 111In-TIL. Cyclophosphamide administration before TIL and IL-2 therapy and the administration of large numbers of TIL appear to improve the frequency of TIL localization to tumor.

AB - Background. The adoptive transfer of interleukin-2 [IL-2]-cultured tumor infiltrating lymphocytes (TIL) can cause tumor regression in patients with metastatic melanoma. Methods. Thirty-eight patients with metastatic melanoma receiving high dose IL-2 and TIL were studied for the ability of autologous 111In-labeled TIL to localize to metastatic tumor deposits by gamma camera imaging and biopsy. Single bolus cyclophosphamide was administered 24-36 hours before TIL infusion in 27 treatment courses. Results. Tumor localization by 111In-labeled TIL was seen by gamma camera imaging in 26 (68.4%) treatment courses. In a univariate analysis of factors influencing TIL traffic, cyclophosphamide administration was significantly associated with the ability to localize tumor by radionuclide imaging (P2 = 0.026). Twenty-one of 26 (80.8%) treatment courses given with cyclophosphamide demonstrated tumor localization, compared with only 5 of 12 (41.7%) treatment courses without cyclophosphamide. In addition, patients whose 111In- labeled TIL imaged their tumor received significantly more TIL than did those that did not (P2 = 0.0052). Biopsies revealed a greater accumulation of 111In in cutaneous tumors than in normal skin biopsy specimens (0.0021 and 0.0004% injectate/gram of tissue, respectively; P2 = 111In-TIL. Cyclophosphamide administration before TIL and IL-2 therapy and the administration of large numbers of TIL appear to improve the frequency of TIL localization to tumor.

KW - cyclophosphamide

KW - immunotherapy

KW - melanoma

KW - radio imaging

KW - tumor infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0028181372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028181372&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 1731

EP - 1737

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -